India Pharma Outlook Team | Tuesday, 06 October 2026
Sterile drug licensing in India could see a major regulatory shift as the Centre considers bringing all sterile drug products under the Central Licensing Approving Authority (CLAA).
The move follows the Supreme Court’s recent refusal to interfere with a Himachal Pradesh High Court ruling that limited the independent enforcement powers of Central Drugs Standard Control Organization (CDSCO) inspectors under Chapter IV of the Drugs and Cosmetics Act.
The Drugs Consultative Committee (DCC) has now recommended a sub-committee to examine the proposal and seek a legal opinion.
The bigger question is how centralization could change compliance, inspections and quality oversight for sterile drug manufacturers.
India’s current regulatory framework divides sterile medicines between central and state licensing authorities.
Large-volume parenterals, sera, vaccines, recombinant DNA-derived products, cell and stem-cell products, gene therapies and xenografts are already covered under the CLAA framework.
Other sterile products, including certain small-volume parenterals, injectables and ophthalmic preparations, are licensed by state authorities.
The proposed expansion is aimed at removing this regulatory fragmentation. The proposal cited differences in application scrutiny and inspection practices between states, particularly when manufacturers seek approval for additional products after receiving a manufacturing license.
A single framework could therefore establish more consistent requirements across sterile-drug manufacturing facilities.
The quality rationale is also significant. Around 240 injection samples were classified as not of standard quality (NSQ) during 2025-26, excluding other sterile dosage forms.
The proposal argues that sterile medicines require specialized oversight because microbial contamination can directly affect product safety.
Also Read: The Evolving Role of India as a Talent Hub for Healthcare R&D
For sterile drug manufacturers in India, central licensing could mean a more uniform compliance pathway but potentially greater regulatory scrutiny.
Manufacturers currently dealing with different state-level processes could eventually operate under common expectations for applications, inspections and product approvals.
This could become particularly important for companies producing injectables, ophthalmic preparations and small-volume parenterals.
A central framework may reduce differences in how applications and inspections are handled across states, while also requiring manufacturers to maintain consistent documentation and quality systems.
The change would also fit into CDSCO’s broader push toward more standardized licensing. Its guidance on dossier-based drug licensing was developed to promote uniformity in the information required from manufacturers across the country.
However, centralization would not automatically mean easier approvals. For manufacturers, the likely trade-off would be greater consistency alongside potentially tighter scrutiny of sterile production, contamination controls and manufacturing practices.
The proposed shift comes amid a wider government effort to strengthen pharmaceutical quality oversight.
CDSCO and state drug authorities have conducted risk-based inspections of more than 960 manufacturing premises since December 2022, resulting in more than 860 regulatory actions, including stop-production orders, license suspensions and cancellations.
For sterile medicines, central oversight could therefore become another layer in this quality push. A common licensing framework could make regulatory expectations more consistent and potentially improve coordination between licensing and inspection authorities.
But central licensing alone will not eliminate quality failures. Its effectiveness will depend on inspection capacity, testing infrastructure, enforcement speed and manufacturer's adherence to good manufacturing practices.
The Centre’s next step is therefore important. The DCC’s proposed sub-committee and legal review could determine whether India moves toward a single central licensing framework for all sterile medicines, potentially reshaping how manufacturers obtain approvals and how regulators oversee one of the country’s most contamination-sensitive drug categories.
.jpg)
